StreetAlpha.app
Home › Stocks › OPK

Opko Health, Inc. (OPK)

Healthcare
$1.62
▲ +0.00%
LAST CLOSE · NOV 17

OPKO Health sells NGENLA growth hormone treatment, Rayaldee kidney disease treatment and specialty lab tests for doctors and patients. It last closed at $1.62 on Nov 17, up 0.00% on the day. OPK last reported earnings on Mon, Jul 27, 2026.

AI Auto Pilots
Is OPK in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$654.1M
+90.8% vs a year ago
Net income
−$148.1M
−22.6% margin
EPS (diluted)
−$0.20
Free cash flow
−$135.3M
−20.7% margin
Valuation
Market cap
$1.2B
742.5M shares
P/E
–
No P/E while losing money
Price to sales
1.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$384.0M
At Sep 30
Debt
$477.4M
At Sep 30
Shareholder equity
$1.1B
Buybacks
$41.9M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.8B$1.8BFY2021FY2022: $1.0B$1.0BFY2022FY2023: $863.5M$863.5MFY2023FY2024: $713.1M$713.1MFY2024FY2025: $606.9M$606.9MFY2025

From OPK's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Last report
Jul 27
2026 · After the close (AMC)
Reported EPS
-$0.01
vs -$0.08 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±25.1%
Priced in before that report
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated OPK in the past 90 days, not enough for a consensus
Average 12-month target
$4.00
▲ 146.9% upside

Based on 1 analyst who set a price target on OPK in the past 90 days. The average target is $4.00, with a high of $4.00 and a low of $4.00, compared with the last close of $1.62.

Low $4.00Avg $4.00High $4.00
Blue marker: last close $1.62
Highest target$4.00
Average target$4.00
Lowest target$4.00
Latest rating changes
Piper SandlerReiterated
Oct 16Buy$4
DateFirmActionRatingPrice target
Oct 16Piper SandlerReiteratedBuy$4
Loading…

Technical Analysis

OPK · as of the Nov 17 close · updated after every close
Moving sideways

The stock sits between its 20 and 50 day averages. It is 16% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 47). The nearest support is the 50 day average at $1.60, and the nearest resistance the Pivot R1 at $1.65.

Short trendNeutral
Long trendBullish
MomentumFading
StretchNormal
VolatilityHigh, 4.9%/day
Key levels
$1.8652 week high+14.8%
$1.6720 day average+3.1%
$1.67Swing high (Oct 26)+3.1%
$1.65Pivot R1+1.9%
$1.62Pivot+0.0%
$1.62Last close
$1.6050 day average−1.2%
$1.59Pivot S1−1.9%
$1.59Swing low (Oct 28)−1.9%
$1.50100 day average−7.4%
$1.37200 day average−15.4%
$0.9852 week low−39.5%
Indicators
RSI (14)47.02Middle of its rangeNeutral
MACD0.02Below its signal lineBearish
Stochastic18.5Near the bottom of its rangeOversold
ADX (14)25.8Trending down
Williams %R-88.9Oversold below −80, overbought above −20Oversold
CCI (20)-83.8Oversold below −100, overbought above 100Neutral
Rate of change−5.8%Change over 10 sessionsBearish
ATR (14)$0.08Typical daily range, 4.9% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for OPK

What happened before

See how OPK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow OPK usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How OPK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in OPK in the last 90 days.

Loading…

See today’s whale options flow across the market →

OPK Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼81 buying vs 99 selling
  • ●Held by funds -0.2 pts
  • ●Funds holding +0
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2242240.0%
In funds' top 1000–
Held by funds27.2%27.4%−0.2 pts
New / increased29 / 5222 / 76−17.3%
Reduced / sold out75 / 2449 / 31+23.8%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OPK institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OPK is in one of them and how their past OPK trades turned out.

OPK in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OPK in an article yet. Here's the latest on the wider market.

About Opko Health

OPKO Health is a healthcare company based in Miami, Florida. It sells NGENLA, a weekly growth hormone treatment for children, and Rayaldee, a treatment for secondary hyperparathyroidism in adults with chronic kidney disease. Its laboratory business provides clinical and women's health testing in New York and New Jersey, along with the 4Kscore prostate cancer test, which is offered across the United States. The company is also developing therapies for cancer and infectious disease.

Headquarters
Miami, FL